TLDR
- Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals on July 6, 2026 in an all-cash deal
- Crinetics stockholders will receive $85 per share
- The deal is valued at $10 billion, or net $8.8 billion after accounting for Crinetics’ cash
- Vertex gains PALSONIFY and atumelnant, two oral endocrinology drugs, plus a broader preclinical pipeline
- Vertex plans to finance the deal with existing cash and a $4.5 billion bridge loan
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals on July 6, 2026 in an all-cash deal worth $10 billion, or net $8.8 billion after Crinetics’ cash holdings.
Crinetics Pharmaceuticals, Inc., CRNX
Crinetics stockholders will receive $85 per share. Unvested equity awards will vest and be cashed out, while deeply out-of-the-money options will be cancelled without payment.
Both boards have unanimously approved the deal. It still requires Hart-Scott-Rodino antitrust review, foreign regulatory clearances, and majority shareholder approval before closing.
A termination fee of approximately $350 million applies under certain circumstances.
Vertex plans to finance the transaction using a mix of its existing cash and new debt. The company has secured a $4.5 billion, 364-day unsecured bridge loan commitment from a bank syndicate, though closing is not contingent on financing availability.
What Vertex Gets from the Deal
The acquisition gives Vertex two key oral endocrinology assets. PALSONIFY is an FDA- and EMA-approved once-daily oral therapy for adults with acromegaly. It launched in the U.S. in October 2025 and was the first oral treatment approved for the condition.
Atumelnant is a once-daily oral ACTH receptor antagonist in late-stage development for congenital adrenal hyperplasia. It is also in Phase 2 trials for ACTH-dependent Cushing’s syndrome.
Beyond those two drugs, Crinetics brings a preclinical pipeline targeting thyroid eye disease, Graves’ disease, and hyperparathyroidism.
Vertex’s Strategic Move into Endocrinology
Vertex says the deal positions it to tap a specialty endocrine market with unmet patient need. The company expects the acquisition to potentially accelerate revenue growth and improve its long-term earnings profile.
VRTX stock was trading up 0.29% at the time of the announcement. The most recent analyst rating on VRTX is a Buy with a $550 price target.
Crinetics, headquartered in San Diego, was a clinical-stage biopharma focused on small-molecule, oral treatments for rare endocrine disorders. Under the deal, it will become a wholly owned subsidiary of Vertex.
Vertex’s current market cap sits at approximately $134 billion.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
